BioSpace News Archive

Expanding research tools to detect small non-coding RNAs in situ by combining molecular information with spatial context.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced changes in the composition and certain roles of its Board of Directors.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, PhD has been appointed Senior Vice President and Chief Financial Officer.

Company Considering Conducting In Vitro Testing Combining Brilacidin with Remdesivir™

- Strategic partnership with Royalty Pharma plc. enables PTC to strengthen and advance its diversified rare disorders portfolio - - Conference call scheduled for 8:30 am ET -

Acerus Announces Launch of NATESTO ® Specialty Sales Team in the United States Initially 22 in Size, Dedicated Staff to Target Urologists and Endocrinologists TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced the launch of a dedicated sales team to promote the Company’s key product,

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing innovative targeted biologic drugs with enhanced mono or bispecific mechanisms, announced today that it has completed initial preclinical proof-of-concept work with both GMcSF and IL-18 and with GMcSF and IL-12 in a xenograft mouse model of melanoma.

- Lantern has entered into agreements with leading contract manufacturing and process development groups to advance manufacturing and development activities on both LP-300 and LP-184. - The manufacturing and process development activity is expected to start immediately and ensure that sufficient drug candidate material will be available for upcoming clinical trials and ongoing research studies.

Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created position of Senior Vice President, Strategy and Business Development. Ms. Ijem joins Krystal from Guggenheim Securities, where she served as Managing Director and Senior Biotechnology Analyst covering genetic me